IL70286A - Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them - Google Patents
Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing themInfo
- Publication number
- IL70286A IL70286A IL70286A IL7028683A IL70286A IL 70286 A IL70286 A IL 70286A IL 70286 A IL70286 A IL 70286A IL 7028683 A IL7028683 A IL 7028683A IL 70286 A IL70286 A IL 70286A
- Authority
- IL
- Israel
- Prior art keywords
- hydrogen
- benzyloxy
- phenoxy
- trifluoromethyl
- fluoro
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
- -1 t-butoxy Chemical group 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44366882A | 1982-11-22 | 1982-11-22 | |
US54885083A | 1983-11-04 | 1983-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL70286A0 IL70286A0 (en) | 1984-02-29 |
IL70286A true IL70286A (en) | 1987-08-31 |
Family
ID=27033614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL70286A IL70286A (en) | 1982-11-22 | 1983-11-21 | Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0114027B1 (fr) |
JP (1) | JPH0347167A (fr) |
AT (1) | ATE31718T1 (fr) |
AU (1) | AU570021B2 (fr) |
CA (1) | CA1210405A (fr) |
CY (1) | CY1579A (fr) |
DE (2) | DE19475017I2 (fr) |
DK (2) | DK359284D0 (fr) |
FI (1) | FI77228C (fr) |
GR (1) | GR79042B (fr) |
HK (1) | HK11191A (fr) |
HU (1) | HU204253B (fr) |
IE (1) | IE56262B1 (fr) |
IL (1) | IL70286A (fr) |
LU (1) | LU88670I2 (fr) |
NL (1) | NL950022I2 (fr) |
NZ (1) | NZ206338A (fr) |
WO (1) | WO1984002131A1 (fr) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4613610A (en) * | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
AU599580B2 (en) * | 1984-12-04 | 1990-07-26 | Sandoz Ag | Indene analogs of mevalonolactone |
US5001255A (en) * | 1984-12-04 | 1991-03-19 | Sandoz Pharm. Corp. | Idene analogs of mevalonolactone and derivatives thereof |
US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
WO1987002662A2 (fr) * | 1985-10-25 | 1987-05-07 | Sandoz Ag | Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques |
US4851427A (en) * | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
US4751235A (en) * | 1986-12-23 | 1988-06-14 | Sandoz Pharm. Corp. | Anti-atherosclerotic indolizine derivatives |
PT85662B (pt) * | 1986-09-10 | 1990-06-29 | Sandoz Sa | Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem |
US4735958A (en) * | 1986-12-22 | 1988-04-05 | Warner-Lambert Company | Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis |
US4898949A (en) * | 1987-02-25 | 1990-02-06 | Bristol-Myers Company | Intermediates for the preparation of antihypercholesterolemic tetrazole compounds |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US4894386A (en) * | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
US4904646A (en) * | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
US5091378A (en) * | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
CA1336714C (fr) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Mevalonolactone de type quinoleine utilisee comme inhibiteurs de la biosynthese du cholesterol |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5185328A (en) * | 1987-08-20 | 1993-02-09 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis |
DE3739882A1 (de) * | 1987-11-25 | 1989-06-08 | Bayer Ag | Substituierte hydroxylamine |
US4868185A (en) * | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
AU2888289A (en) * | 1988-01-27 | 1989-07-27 | May & Baker Limited | Isoquinolinones |
US4822799A (en) * | 1988-01-27 | 1989-04-18 | Sandoz Pharm. Corp. | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals |
NO890522L (no) * | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte imidazolinoner og imidazolinthioner. |
JP2890448B2 (ja) * | 1988-04-26 | 1999-05-17 | 日産化学工業株式会社 | ピラゾロピリジン系メバロノラクトン類 |
US5024999A (en) * | 1988-04-26 | 1991-06-18 | Nissan Chemical Industries Ltd. | Pyrazolopyridine type mevalonolactones useful as pharmaeuticals |
US4870187A (en) * | 1988-08-23 | 1989-09-26 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl compounds |
US5010205A (en) * | 1988-08-23 | 1991-04-23 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl intermediates |
NZ230121A (en) * | 1988-08-29 | 1993-08-26 | Squibb & Sons Inc | Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels |
US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
IL91941A (en) * | 1988-10-13 | 1994-10-21 | Sandoz Ag | Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a) |
JPH04270285A (ja) * | 1988-11-14 | 1992-09-25 | Nissan Chem Ind Ltd | ピラゾロピリミジン系メバロノラクトン類 |
DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB8919091D0 (en) * | 1989-08-22 | 1989-10-04 | Fujisawa Pharmaceutical Co | Pyrroloquinoline compounds |
IT1237792B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
JP2736599B2 (ja) * | 1993-07-23 | 1998-04-02 | 株式会社キッツ | ボールバルブのシート構造 |
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
DK0907639T3 (da) * | 1996-06-24 | 2003-06-23 | Novartis Ag | Polymorfe forbindelser |
WO1998055454A2 (fr) | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Composes heterocycliques, leur preparation et leur utilisation |
US7939105B2 (en) | 1998-11-20 | 2011-05-10 | Jagotec Ag | Process for preparing a rapidly dispersing solid drug dosage form |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
CA2407862A1 (fr) | 2000-05-26 | 2001-12-06 | Ciba Specialty Chemicals Holding Inc. | Processus de preparation de derives indole et d'intermediaires de ce processus |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
CA2444028A1 (fr) | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Methodes pour traiter le syndrome x avec des polyamines aliphatiques |
CN1536999B (zh) * | 2001-08-03 | 2012-08-08 | 西巴特殊化学品控股有限公司 | 氟伐他汀钠的晶形 |
WO2003060078A2 (fr) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulateurs heterocycliques de recepteurs nucleaires |
EP1496897A4 (fr) | 2002-04-12 | 2006-05-10 | Merck & Co Inc | Inhibiteurs de tyrosines kinases |
US7312353B2 (en) | 2003-08-21 | 2007-12-25 | Merck Frost Canada & Co. | Cathespin cysteine protease inhibitors |
EP1510208A1 (fr) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Compositions pharmaceutiques comprenant une combinaison de metformine et de statine |
CN100404479C (zh) * | 2003-08-27 | 2008-07-23 | 住友化学株式会社 | 芳族不饱和化合物的制备方法 |
US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
WO2006062876A2 (fr) * | 2004-12-09 | 2006-06-15 | Merck & Co., Inc. | Modulateurs du recepteur de l'oestrogene |
US7709508B2 (en) | 2004-12-09 | 2010-05-04 | Merck Sharp & Dohme | Estrogen receptor modulators |
EP1855674B1 (fr) | 2005-03-02 | 2014-07-16 | Merck Sharp & Dohme Corp. | Composition destinee a l'inhibition de cathepsine k |
CA2613517A1 (fr) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Modulateurs des lxr a base de pyrazoles |
US8354530B2 (en) | 2005-07-28 | 2013-01-15 | Lek Pharmaceuticals d. d | Process for the synthesis of rosuvastatin calcium |
US8440695B2 (en) | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
TW200813039A (en) | 2006-04-19 | 2008-03-16 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
EP1847529B1 (fr) | 2006-04-20 | 2009-05-20 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Procédé de préparation de la fluvastatine sodique |
PT2363130E (pt) | 2006-07-05 | 2014-06-25 | Takeda Gmbh | Combinação de atorvastatina ou sinvastatina, inibidores de hmg-coa redutase, com um inibidor da fosfodiesterase 4, tal como roflumilaste, para o tratamento de doenças pulmonares inflamatórias |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
ES2330184B1 (es) | 2008-06-03 | 2010-07-05 | Neuron Biopharma, S.A. | Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores. |
EP2373609B1 (fr) | 2008-12-19 | 2013-10-16 | KRKA, D.D., Novo Mesto | Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines |
EP2327682A1 (fr) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Utilisation de composés amphiphiles pour la crystallisation controlée de statines et d'intermediaires de statines. |
CA2761934C (fr) | 2009-05-28 | 2018-01-09 | Exelixis Patent Company Llc | Composes de 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole substitue et leur utilisation comme modulateur lxr |
WO2010144909A1 (fr) | 2009-06-12 | 2010-12-16 | Novartis Ag | Composés hétérocycliques fondus et leurs utilisations |
WO2011090738A2 (fr) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase raf de type ii |
EA201290919A1 (ru) | 2010-03-16 | 2013-03-29 | Дана-Фарбер Кэнсер Инститьют, Инк. | Индазольные соединения и их применение |
US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
CN103153299A (zh) | 2010-10-06 | 2013-06-12 | 国立大学法人东京大学 | 淋巴水肿预防治疗剂 |
US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
BR112014016154A8 (pt) | 2011-12-29 | 2017-07-04 | Tufts College | funcionalização de biomateriais para controlar respostas à regeneração e inflamação |
EP2909194A1 (fr) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
EP2810644A1 (fr) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Formulation orale pour le traitement de maladies cardiovasculaires |
WO2015051479A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de cystéine-protéases de type cathepsines |
AU2014332250B2 (en) | 2013-10-08 | 2018-07-19 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
CA2927917C (fr) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Composes heteroaromatiques utiles pour le traitement des maladies proliferatives |
WO2015120580A1 (fr) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Inhibiteurs de protéases à cystéine de type cathépsines |
WO2015164614A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase et leurs utilisations |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
EP3236959A4 (fr) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2016201370A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
-
1983
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/fr active IP Right Grant
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-22 EP EP83810548A patent/EP0114027B1/fr not_active Expired
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 CA CA000441684A patent/CA1210405A/fr not_active Expired
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
-
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284D0/da not_active Application Discontinuation
-
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
-
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
-
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
AU570021B2 (en) | 1988-03-03 |
EP0114027B1 (fr) | 1988-01-07 |
JPH0347167A (ja) | 1991-02-28 |
HUT35642A (en) | 1985-07-29 |
IE56262B1 (en) | 1991-06-05 |
HK11191A (en) | 1991-02-13 |
HU204253B (en) | 1991-12-30 |
DK359284A (da) | 1984-07-20 |
DK97890D0 (da) | 1990-04-19 |
JPH0440343B2 (fr) | 1992-07-02 |
ATE31718T1 (de) | 1988-01-15 |
CA1210405A (fr) | 1986-08-26 |
FI842615A (fi) | 1984-06-28 |
FI77228B (fi) | 1988-10-31 |
NZ206338A (en) | 1987-08-31 |
AU2261283A (en) | 1984-06-18 |
GR79042B (fr) | 1984-10-02 |
NL950022I1 (fr) | 1996-01-02 |
DE19475017I2 (de) | 2003-02-20 |
IE832713L (en) | 1984-05-22 |
EP0114027A1 (fr) | 1984-07-25 |
FI77228C (fi) | 1989-02-10 |
DE3375137D1 (en) | 1988-02-11 |
LU88670I2 (fr) | 1996-04-29 |
WO1984002131A1 (fr) | 1984-06-07 |
DK165244C (da) | 1993-03-22 |
NL950022I2 (nl) | 1996-12-02 |
CY1579A (en) | 1991-12-20 |
FI842615A0 (fi) | 1984-06-28 |
DK97890A (da) | 1990-04-19 |
DK359284D0 (da) | 1984-07-20 |
DK165244B (da) | 1992-10-26 |
IL70286A0 (en) | 1984-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL70286A (en) | Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them | |
DE3460035D1 (en) | 1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and formulations containing it | |
MY105158A (en) | Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors. | |
AU570942B2 (en) | Analogs of mevalonolactone and derivatives thereof, processesfor their production, pharmaceutical compositions containing them and their use as pharmaceuticals | |
DE3067201D1 (en) | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
FI895046A0 (fi) | 4-amino-3-acylkinolinderivat samt deras anvaendning saosom inhibitorer av sekretion av matsmaeltningsvaetskor. | |
ES2010284A6 (es) | Procedimiento para preparar derivados de tiourea. | |
GB2160525A (en) | 8,10-dideazaminopterins | |
ES8506660A1 (es) | Un procedimiento para la preparacion de un compuesto de b-lactama |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of name of proprietor(s) | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |